Kernal Biologics has been awarded up to $48 million in funding to accelerate the development of KR-402, a next-generation CAR T-cell therapy for multiple sclerosis (MS) and certain blood cancers. The funds […]
The post Kernal gets $48M to develop easier, cheaper CAR T-cell therapies appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com